Charles Sawyers and colleagues have conducted a small early-stage clinical study to assess target modulation by the small-molecule inhibitor rapamycin. Rapamycin is approved to treat renal cancer ...

17/391.495 titled “Oral Rapamycin Nanoparticle Preparations and Use” which was exclusively licensed to Biodexa by Rapamycin Holdings, Inc. d/b/a Emtora Biosciences, along with other patents ...